Toxicol., 45(1), 6-9
(2003).
7. Wang, Y., et al., Brain uptake of
dihydroergotamine after intravenous and nasal
administration in the rat. Biopharm. Drug Dispos.,
19(9), 571-575 (1998).
8.
C-Terminal A8344 8996 NOL3 P NP_001171986.1 y n/d n/d
762 WSTF W3516 9031 BAZ1B P NP_115784.1, y y n/d
571 PIAS-x P9498 9063 PIAS2 M NP_004662.2 y n/d n/d
466 MTA1 M1320 9112 MTA1 M NP_001190187.1 y y y
467
C-Terminal A8344 8996 NOL3 P NP_001171986.1 y n/d n/d
762 WSTF W3516 9031 BAZ1B P NP_115784.1, y y n/d
571 PIAS-x P9498 9063 PIAS2 M NP_004662.2 y n/d n/d
466 MTA1 M1320 9112 MTA1 M NP_001190187.1 y y y
467
C-Terminal A8344 8996 NOL3 P NP_001171986.1 y n/d n/d
762 WSTF W3516 9031 BAZ1B P NP_115784.1, y y n/d
571 PIAS-x P9498 9063 PIAS2 M NP_004662.2 y n/d n/d
466 MTA1 M1320 9112 MTA1 M NP_001190187.1 y y y
467
γ1) P8104 P y y n/d
569 PhosphatidylSerine Receptor (PSR) P1495 P y y n/d
570 Negative Control NA
571 PIAS-x P9498 M y n/d n/d
572 Negative Control NA
573 PINCH-1 P9371 M y y y
574 Protein Kinase Bα /Akt1
M. Drug Res. 2020, 70, 6–11.
(178) Tiwari, S.; Bahadur, P. Int. J. Biol. Macromol. 2019, 121, 556–571.
(179) López-Marcial, G. R.; Zeng, A. Y.; Osuna, C.; Dennis, J.; García, J. M.;
O’Connell, G. D
Receptor (PSR) P1495 23210, 107817 PTDSR,Ptdsr NP_055982.2,NP_203971.2 P y y n/d
570 Negative Control NA
571 PIAS-x P9498 9063 PIAS2 NP_775298.1 M y n/d n/d
572 Negative Control NA 361724, 23942, 9219 MTA2,Mta2
M. Drug Res. 2020, 70, 6–11.
(178) Tiwari, S.; Bahadur, P. Int. J. Biol. Macromol. 2019, 121, 556–571.
(179) López-Marcial, G. R.; Zeng, A. Y.; Osuna, C.; Dennis, J.; García, J. M.;
O’Connell, G. D
ETHYL 2-METHYLBUTYRATE NATURAL, MIXTURE OF
ENANTIOMERS, 98%, FCC, FG
W244317 B80172 HC-23SI4V03
571. ETHYL 2-TRANS-4-CIS-DECADIENOATE 80% W314803 B55781 HC-23SIRB32
This is to certify that the following
ETHYL 2-METHYLBUTYRATE NATURAL, MIXTURE OF
ENANTIOMERS, 98%, FCC, FG
W244317 B80172 HC-22SI7B24
571. ETHYL 2-TRANS-4-CIS-DECADIENOATE 80% W314803 B55781 HC-22SIHI53
This is to certify that the following